welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.
expertly curated content related to this topic
-
Joann N. Bodurtha, MD, MPHDr. Joann Bodurtha is a professor of ped...
-
#FAPAwarenessFAP hashtag for the community...
-
University Hospitals Cleveland Medical CenterThe history of University Hospitals Clev...
-
Robert Daniel Odze, MD, FRCPCRobert Daniel Odze is a Professor of Pat...
-
John M. Carethers, MDCurrent Position: Professor, Internal Me...
-
mitchell w. dillonDirector of Genetic Counseling Services ...
-
Banner MD Anderson Cancer CenterAt Banner MD Anderson Cancer Center, col...